Crossmark

“Real-world” radiomics from multi-vendor MRI: an original retrospective study on the prediction of nodal status and disease survival in breast cancer, as an exemplar to promote discussion of the wider issues

Crossref DOI link: https://doi.org/10.1186/s40644-021-00406-6

Published Online: 2021-05-20

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Doran, Simon J. https://orcid.org/0000-0001-8569-9188
Kumar, Santosh

Orton, Matthew

d’Arcy, James

Kwaks, Fenna

O’Flynn, Elizabeth

Ahmed, Zaki

Downey, Kate

Dowsett, Mitch

Turner, Nicholas

Messiou, Christina

Koh, Dow-Mu
Funding

Funding for this research was provided by:

National Institute for Health Research

Cancer Research UK (C1060/A10334, C1060/A16464)

Engineering and Physical Sciences Research Council
License Information

Text and Data Mining valid from 2021-05-20

Version of Record valid from 2021-05-20
More Information

Article History

Received: 10 November 2020

Accepted: 12 April 2021

First Online: 20 May 2021

Declarations

:

: This was a retrospective study, which was approved by our institutional review board.

: Not applicable.

: The authors declare that they have no competing interests.Nicholas Turner has received advisory board honoraria from Astra Zeneca, Bristol-Myers Squibb, Lilly, Merck Sharpe and Dohme, Novartis, Pfizer, Roche/Genentech, Bicycle Therapeutics, Taiho, Zeno pharmaceuticals, Repare therapeutics and research funding from Astra Zeneca, BioRad, Pfizer, Roche/Genentech, Clovis, Merck Sharpe and Dohme, and Guardant Health.

Document is current

Any future updates will be listed below